Keywords: trovax, impresses, ph, ii, mcrc, trial, uk-based

TroVax impresses in Ph II mCRC trial

Article | 13 August 2007

Print This

UK-based biopharmaceutical firm Oxford Biomedica says that data from a Phase II study of its immunotherapy product TroVax, which is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in